Fully hybrid 18F-PSMA PET/MRI as one-stop approach for the diagnosis of clinically significant prostate cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512859-21-00

Enrollment

167

Registered

2024-10-21

Start date

2023-12-04

Completion date

Unknown

Last updated

2025-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with clinical suspicion of clinically relevant prostate cancer

Brief summary

Diagnostic accuracy measured by sensitivity, specificity, and positive and negative predictive values

Interventions

DRUG[18F]PSMA-1007

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy measured by sensitivity, specificity, and positive and negative predictive values	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026